Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Icosapent ethyl is a highly purified formulation of eicosapentaenoic acid, a type of omega-3 fatty acid contained in fish oil. While omega-3 fatty acids have long been thought to have cardioprotective benefits, the Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) has helped to establish icosapent ethyl as an evidence-based therapy for risk reduction of atherosclerotic cardiovascular disease (ASCVD). REDUCE-IT, however, was by no means an overnight success story. Close examination of the evidence shows that the trial was a culmination of many lessons learned from previous studies. The purpose of this manuscript is to review contemporary evidence of icosapent ethyl in ASCVD risk reduction and the clinical implication of this promising therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It remains unclear as to why these differences exist and brings to the fore the hypothesis that triglycerideindependent effects of EPA may be in part responsible for the CV benefits seen in the REDUCE-IT trial”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Üstün, Y. E. (2019) · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · Cited by 169,581
Home visits: a strategy to improve newborn survival - Authors' reply
(2008) · Americanae (AECID Library) · doi:10.1016/s0140 · Cited by 22,524
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317 · cited 2×
“98).(35) There was actually a lower rate of gastrointestinal adverse events, though this may be attributable to the use of mineral oil as the placebo.”
BackgroundResult(2005) · The Lancet · doi:10.1016/s0140-6736(05)67667-2 · Cited by 3,284 · cited 1×
“pies such as fibrates and niacin have not shown to improve cardiovascular outcomes.(8,9) EPA Effects on Lipids, Lipoproteins and Markers of Inflammation Omega-3 FA agents are known to reduce TGs and have been used for the treatment of hypertriglyceridemia.”
BackgroundPro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041 · cited 1×
“SPMs play an important role in counter-regulation of inflammation including in atherosclerosis.(29,30) When”
Background
Research works printed but not linked: 2
- [58]Institute for Clinical and Economic Review. Additive Therapies for Cardiovascular Disease: Effectiveness and Value; 2019 Available from: https://icer-review.org/wp-content/uploads/2019/02/ICER_CVD_Draft_Evidence_Report_072419.pdf. Accessed December 2, 2019.
- [60]UMIN-CTR Clinical Trial. Randomized trial for evaluation in secondary prevention efficacy of combination therapy — statin and eicosapentaenoic acid UMIN000012069; 2018. Available from: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014051. Accessed November 22, 2019. 38873793
Cited by
Chapman, M. J., Zamorano, J. L., & Parhofer, K. G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108172 · Cited by 67
Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids
Weinberg, R. L., Brook, R. D., Rubenfire, M., & Eagle, K. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.060 · Cited by 63
Triglycerides and ASCVD risk reduction: recent insights and future directions
Hussain, A., Ballantyne, C. M., Saeed, A., & Virani, S. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00846-8 · Cited by 57
Self-citationRegular use of fish oil supplements and course of cardiovascular diseases: prospective cohort study
Chen, G., Qian, Z. M., Zhang, J., Zhang, S., Zhang, Z., Vaughn, M. G., Aaron, H. E., Wang, C., Lip, G. Y. H., & Lin, H. (2024) · BMJ Medicine · doi:10.1136/bmjmed-2022-000451 · Cited by 51
“31 No proven biological mechanism for this explanation exists, however, and the dose and formulation of omega 3 fatty acids used in clinical practice are not known.”
BackgroundThe multidimensional benefits of eicosapentaenoic acid: from heart health to inflammatory control
Nassar, M., Jaffery, A., Ibrahim, B., Baraka, B., & Abosheaishaa, H. M. (2023) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-023-00265-6 · Cited by 26
Jia, X., Rifai, M. A., Liu, J., Agarwala, A., Gulati, M., & Virani, S. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00856-6 · Cited by 12
Self-citationLiu, X., Wang, W., Li, Q., Niu, H., & Zhang, W. (2024) · International Journal of Smart and Nano Materials · doi:10.1080/19475411.2024.2395270 · Cited by 9
“…indicated purified form of ethyl esters (icosapent ethyl) EPA at daily dose of 4 grams was effective in reducing cardiovascular events and death in patients with ASCVD or diabetes and multiple cardiovascular risk factors, in addition to elevated triglycerides, while being on statin regimen [30].”
Advances in Primordial, Primary, and Secondary Prevention of Stroke in Diverse Populations
Adeniji, O. A., Olowoyo, P., Akinyemi, R., Fisher, M., & Owolabi, M. O. (2024) · Stroke · doi:10.1161/strokeaha.123.044231 · Cited by 9
Hussain, A., Rifai, M. A., Mahtta, D., Liu, J., Jain, V., & Virani, S. S. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00900-5 · Cited by 6
Self-citationAlcohol: the role in nutrition and health
Suter, P. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818460-8.00025-3 · Cited by 5
Kłosiewicz−Latoszek, L., Cybulska, B., & Tyszko, P. Z. (2020) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/126674 · Cited by 4
“8 g/d in patients with a history of coronary artery disease, and is expected to end in 2022 [23].”
BackgroundResultEmphasis on Icosapent Ethyl for Cardiovascular Risk Reduction: A Systematic Review
Sutariya, B., Montenegro, D. M., Chukwu, M., Ehsan, P., Aburumman, R. N., Muthanna, S. I., Menon, S. R., Vithani, V., & Penumetcha, S. S. (2022) · Cureus · doi:10.7759/cureus.32346 · Cited by 5
“While there was no difference between the IPE and placebo groups in terms of new heart failure or heart failure hospitalization [18].”
BackgroundInfluentialBhatt, A., Dubey, S. K., & Bhatt, A. K. (2021) · International Conference on Cloud Computing, Data Science & Engineering (Confluence) · doi:10.1109/confluence51648.2021.9377092 · Cited by 2
Defining the Role of Icosapent Ethyl in Clinical Practice
Chatterjee, S., Hajra, A., Bandyopadhyay, D., Ghosh, R. K., & DEEDWANIA, P. C. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00402-4 · Cited by 1
Metadata
- Authors
- Jia, X., Koh, S., Al Rifai, M., Blumenthal, R. S., & Virani, S. S.
- Affiliations
- Baylor College of Medicine (US)
- Johns Hopkins University (US)
- Michael E. DeBakey VA Medical Center (US)
- Corresponding author
- Virani, Salim S
- Venue
- Vascular Health and Risk Management
- Publisher
- Informa UK Limited
- Published
- 2020-01
- Volume
- Volume 16
- Pages
- 1-10
- ISSN
- 1176-6344 (ISSN-L)
- 1178-2048
- PMC
- PMC6957107
- OpenAlex
- W3000366026
- Cited by
- 14
- References
- 69
- Citations by year
- 2024: 3 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 5
- FWCI
- 0.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Vascular Health and Risk Management (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (acceptedVersion)
- eCommons - AKU (Aga Khan University) (submittedVersion, cc-by-nc)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Keywords
- icosapent ethyl, eicosapentaenoic acid, omega-3 fatty acids, fish oil, atherosclerotic cardiovascular disease, cardiovascular risk reduction, REDUCE-IT trial, cardioprotection
- MeSH terms
- Animals, Cardiovascular Diseases, Humans, Risk Factors, Eicosapentaenoic Acid, Risk Assessment, Evidence-Based Medicine, Dietary Supplements, Protective Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.